Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content
Figure 1 | Molecular Pain

Figure 1

From: BDNF regulates atypical PKC at spinal synapses to initiate and maintain a centralized chronic pain state

Figure 1

Lack of involvement of CaMKIIα or MAPK in persistent sensitization. A) IL-6 was injected into the left hindpaw (i.pl.) of mice and myr-CamKIINTide (peptide CaMKIIα inhibitor) or the non-myristolyated control were injected i.t. at the same time testing the initiation of persistent sensitization. Hindpaw mechanical thresholds were measured at indicated time points. Myr-CamKIINTide inhibited allodynia induced by IL-6 injection (left) and attenuated PGE2-precipitated persistent sensitization (right). B) On the other hand, Myr-CamKIINTide administered i.t. on day 4 after IL-6 injection had no effect on PGE2-precipitated persistent sensitization. C) Likewise, no effect was observed in the same experimental paradigm with the small molecule CaMKIIα inhibitor KN93. D) IL-6 was injected i.pl. and the MEK inhibitor U0126 or VEH control were injected i.t. at the same time testing the initiation of persistent sensitization. U0126 inhibited allodynia induced by IL-6 injection (left) and attenuated PGE2-precipitated persistent sensitization (right). E) However, U0126 given i.t. 4 days after IL-6 had no effect on PGE2-precipitated persistent sensitization. All experiments N = 6. * p < 0.05, ** p < 0.01, *** p < 0.001, two way ANOVA with Bonferroni post hoc test.

Back to article page